

**LUPUS AND ALLIED
DISEASES ASSOCIATION, INC.
VERONA, NY**

**FINANCIAL STATEMENTS
AT SEPTEMBER 30, 2023**

C O N T E N T S

Auditor's report	1 - 2
Statements of financial position	3
Statements of activities	4 - 5
Statements of functional expenses	6 - 7
Statements of cash flows	8
Notes to financial statements	9 - 11

INDEPENDENT AUDITORS' REPORT

To the Board of Directors
Lupus and Allied Diseases Association, Inc.
Verona, New York

Report on the Financial Statements

We have audited the accompanying balance sheets of Lupus and Allied Diseases Association, Inc. as of September 30, 2023 and 2022, and the related statements of income, retained earnings, and cash flows for the years then ended, and the related notes to the financial statements.

Management's Responsibility for the Financial Statements

Management is responsible for the preparation and fair presentation of these financial statements in accordance with accounting principles generally accepted in the United States of America; this includes the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of consolidated financial statements that are free from material misstatement, whether due to fraud or error.

Auditor's Responsibility

Our responsibility is to express an opinion on these financial statements based on our audits. We conducted our audits in accordance with auditing standards generally accepted in the United States of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and the disclosures in the financial statements. The procedures selected depend on the auditor's judgement, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the entity's preparation and fair presentation of the financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity's internal control. Accordingly, we express no such opinion. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluating the overall presentation of the financial statement.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a reasonable basis for our audit opinion.

Opinion

In our opinion, the financial statements referred to previously present fairly, in all material respects, the financial position of Lupus and Allied Diseases Association, Inc. as of September 30, 2023 and 2022, and the results of its operations and its cash flows for the years then ended in conformity with accounting principles generally accepted in the United States of America.

A handwritten signature in black ink, appearing to read 'A. Lamirande', with a stylized flourish at the end.

Andrew J Lamirande, CPA, Esq.

January 15, 2024

LUPUS AND ALLIED DISEASES ASSOCIATION, INC.

STATEMENTS OF FINANCIAL POSITION
SEPTEMBER 30, 2023 AND 2022

	<u>2023</u>	<u>2022</u>
ASSETS		
Cash and cash equivalents	\$ 301,604	\$ 325,618
Short-term investments	1,944,624	1,618,228
Accounts receivable, net of bad debts	-	-
Prepaid expenses	-	-
Unconditional promises to give	-	-
Long-term investments	-	-
Contributions receivable	-	-
Property and equipment, net	<u>317</u>	<u>528</u>
TOTAL ASSETS	<u>\$ 2,246,545</u>	<u>\$ 1,944,374</u>
 LIABILITIES		
Accounts payable	\$ -	\$ -
Refundable Advances	-	-
Long-term debt	<u>-</u>	<u>-</u>
TOTAL LIABILITIES	-	-
 NET ASSETS		
Unrestricted		
Designated for new program development	-	-
Undesignated	2,246,545	1,944,374
Temporarily restricted	-	-
Permanently restricted	<u>-</u>	<u>-</u>
TOTAL NET ASSETS	<u>2,246,545</u>	<u>1,944,374</u>
TOTAL LIABILITIES AND NET ASSETS	<u>2,246,545</u>	<u>1,944,374</u>

See accompanying notes and accountants' report.

LUPUS AND ALLIED DISEASES ASSOCIATION, INC.

STATEMENT OF ACTIVITIES
YEAR ENDED SEPTEMBER 30, 2023

	<u>Unrestricted</u>	<u>Temporarily Restricted</u>	<u>Permanently Restricted</u>	<u>Total</u>
REVENUES, GAINS, AND OTHER SUPPORT				
Contributions	\$ 808,660	\$ -	\$ -	\$ 808,660
Special events	185,900			185,900
Investment return	46,627	-	-	46,627
Net assets released from restrictions	-	-	-	-
	<hr/>	<hr/>	<hr/>	<hr/>
TOTAL REVENUES, GAINS, AND OTHER SUPPORT	\$ 1,041,187	-	-	1,041,187
EXPENSES				
Direct donor benefit expenses - special events	31,657			31,657
Program services				
Advocacy	67,056	-	-	67,056
Awareness	34,249	-	-	34,249
Education	71,969	-	-	71,969
Research	531,400	-	-	531,400
Supporting services				
Management and general	2,111	-	-	2,111
Fundraising	574	-	-	574
	<hr/>	<hr/>	<hr/>	<hr/>
TOTAL EXPENSES	739,016	-	-	739,016
CHANGE IN NET ASSETS	302,171			302,171
NET ASSETS AT BEGINNING OF YEAR	<hr/> 1,944,374	<hr/> -	<hr/> -	<hr/> 1,944,374
NET ASSETS AT END OF YEAR	\$ 2,246,545	\$ -	\$ -	\$ 2,246,545

See accompanying notes and auditor's report.

LUPUS AND ALLIED DISEASES ASSOCIATION, INC.

STATEMENT OF ACTIVITIES
YEAR ENDED SEPTEMBER 30, 2022

	<u>Unrestricted</u>	<u>Temporarily Restricted</u>	<u>Permanently Restricted</u>	<u>Total</u>
REVENUES, GAINS, AND OTHER SUPPORT				
Contributions	\$ 949,023	\$ -	\$ -	\$ 949,023
Special events	149,307			149,307
Investment return	10,848	-	-	10,848
Net assets released from restrictions	-	-	-	-
	<hr/>	<hr/>	<hr/>	<hr/>
TOTAL REVENUES, GAINS, AND OTHER SUPPORT	\$ 1,109,178	-	-	1,109,178
EXPENSES				
Direct donor benefit expenses - special events	27,312			27,312
Program services				
Advocacy	27,711	-	-	27,711
Awareness	12,116	-	-	12,116
Education	48,192	-	-	48,192
Research	450,200	-	-	450,200
Supporting services				
Management and general	1,877	-	-	1,877
Fundraising	643	-	-	643
	<hr/>	<hr/>	<hr/>	<hr/>
TOTAL EXPENSES	568,051	-	-	568,051
CHANGE IN NET ASSETS	541,127			541,127
NET ASSETS AT BEGINNING OF YEAR	<hr/> 1,403,247	<hr/> -	<hr/> -	<hr/> 1,403,247
NET ASSETS AT END OF YEAR	\$ 1,944,374	\$ -	\$ -	\$ 1,944,374

See accompanying notes and accountants' report.

LUPUS AND ALLIED DISEASES ASSOCIATION, INC.

STATEMENT OF FUNCTIONAL EXPENSES
YEAR ENDED SEPTEMBER 30, 2023

	Program Services				Supporting Services	
	Advocacy	Awareness	Education	Research	Management and general	Special events
Compensation and related expense	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -
Conference and training	-	-	-	-	-	-
Depreciation	60	60	59	-	21	11
Food	-	-	-	-	-	-
Insurance	773	773	774	-	129	129
Interest	-	-	-	-	-	-
Information technology	955	955	955	-	160	159
Maintenance of equipment	-	-	-	-	-	-
Postage	-	-	-	-	-	-
Printing	-	-	-	-	-	-
Professional fees	416	417	417	-	1,250	-
Research Grants	-	-	-	531,400	-	-
Supplies	-	-	-	-	-	-
Office	1,653	1,653	1,653	-	276	275
Other	-	-	-	-	-	-
Telephone	-	-	-	-	-	-
Transportation	-	-	-	-	-	-
Fuel	-	-	-	-	-	-
Repairs and other	-	-	-	-	-	-
Other	63,199	30,391	68,111	-	275	-
	\$ 67,056	\$ 34,249	\$ 71,969	\$ 531,400	\$ 2,111	\$ 574

See accompanying notes and auditor's report.

LUPUS AND ALLIED DISEASES ASSOCIATION, INC.

STATEMENT OF FUNCTIONAL EXPENSES
YEAR ENDED SEPTEMBER 30, 2022

	Program Services				Supporting Services	
	Advocacy	Awareness	Education	Research	Management and general	Special events
Compensation and related expense: \$	-	\$ -	\$ -	\$ -	\$ -	\$ -
Conference and training	-	-	-	-	-	-
Depreciation	176	176	175	-	62	31
Food	-	-	-	-	-	-
Insurance	784	784	784	-	131	130
Interest	-	-	-	-	-	-
Information technology	706	706	705	-	118	117
Maintenance of equipment	-	-	-	-	-	-
Postage	-	-	-	-	-	-
Printing	-	-	-	-	-	-
Professional fees	308	308	309	-	925	-
Research grants	-	-	25,500	450,200	-	-
Supplies	-	-	-	-	-	-
Office	2,194	2,193	2,193	-	366	365
Other	-	-	-	-	-	-
Telephone	-	-	-	-	-	-
Transportation	-	-	-	-	-	-
Fuel	-	-	-	-	-	-
Repairs and other	-	-	-	-	-	-
Other	23,543	7,949	18,526	-	275	-
	\$ 27,711	\$ 12,116	\$ 48,192	\$ 450,200	\$ 1,877	\$ 643

See accompanying notes and auditor's report.

LUPUS AND ALLIED DISEASES ASSOCIATION, INC.

STATEMENT OF CASH FLOWS
SEPTEMBER 30, 2023 AND 2022

	<u>2023</u>	<u>2022</u>
CASH FLOWS FROM OPERATING ACTIVITIES:		
Increase in net assets	\$ 302,171	\$ 541,127
Adjustments to reconcile increase in net assets to net cash provided by operating activities:		
Depreciation	211	620
Unrealized gains on investments	-	-
(Increase) decrease in operating assets:		
Accounts receivable	-	-
Prepaid expenses	-	-
Unrestricted promises to give	-	-
Contributions receivable	-	-
Increase (decrease) in operating liabilities		
Accounts payable	-	-
Compensation	-	-
Refundable advances	-	-
Contributions restricted for long-term purposes:		
Contributions	-	-
Amortization of discount on unconditional promises to give	-	-
NET CASH PROVIDED BY OPERATING ACTIVITIES	<u>302,382</u>	<u>541,747</u>
CASH FLOWS FROM INVESTING ACTIVITIES		
Short-term investments, net	(326,396)	(1,107,752)
Purchases of long-term investments	-	-
Proceeds from maturity of long-term investments	-	-
Payments for property and equipment	-	-
Purchase of assets restricted to investment in property and equipment	-	-
Other	-	-
NET CASH USED BY INVESTING ACTIVITIES	<u>(326,396)</u>	<u>(1,107,752)</u>
CASH FLOWS FROM FINANCING ACTIVITIES		
Collections of contributions restricted for long-term purposes	-	-
Payments on loans	-	-
NET CASH PROVIDED BY FINANCING ACTIVITIES	<u>-</u>	<u>-</u>
NET INCREASE (DECREASE) IN CASH AND EQUIVALENTS	(24,014)	(566,005)
BEGINNING CASH AND CASH EQUIVALENTS	<u>\$ 325,618</u>	<u>\$ 891,623</u>
ENDING CASH AND CASH EQUIVALENTS	301,604	325,618

See accompanying notes and auditor's report.

LUPUS AND ALLIED DISEASES ASSOCIATION, INC.

NOTES TO FINANCIAL STATEMENTS
AT SEPTEMBER 30, 2023

NOTE A – NATURE OF ACTIVITIES AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

NATURE OF ACTIVITIES

Lupus and Allied Diseases Association, Inc. (the Organization) provides public, governmental, and private education and awareness to those interested in lupus and autoimmune diseases throughout the United States. The Organization also supports research and advocates for the advancement of treatment and cures for autoimmune diseases. The Organization is supported primarily through donor contributions, grants, and special events. Approximately 19% and 14% of the Organization's support for the years ended September 30, 2023 and 2022, respectively, came from special events.

BASIS OF ACCOUNTING

The Organization's policy is to prepare its financial statements on the accrual basis of accounting in conformity with accounting principles generally accepted in the United States of America ("GAAP").

CONTRIBUTED SERVICES

During the years ended September 30, 2023 and 2022, the value of contributed services meeting the requirements for recognition in the financial statements was not material and has not been recorded. In addition, individuals volunteer their time and expertise to perform a variety of tasks that assist the Organization in their awareness and education efforts. For the year ended September 30, 2023, volunteer hours amounted to 9,212 total hours amounting to \$328,960 valued at the Independent Sector's State Values of Volunteer Time rate of \$35.71 per hour. For the year ended September 30, 2022, volunteer hours amounted to 9,000 total hours amounting to \$311,310 valued at the Independent Sector's State Values of Volunteer Time rate of \$34.59 per hour.

INCOME TAXES

The Organization has been classified by the Internal Revenue Service as a corporation described under 501(c)(3) of the Internal Revenue Code ("the Code") as exempt from federal income taxes under section 501(a) of the Code. The Organization is subject to a tax on income from any unrelated business.

CASH AND CASH EQUIVALENTS

For purposes of the statements of cash flows, the Organization considers all highly liquid investments available for current use with an initial maturity of three months or less to be cash equivalents.

LUPUS AND ALLIED DISEASES ASSOCIATION, INC.

NOTES TO FINANCIAL STATEMENTS
AT SEPTEMBER 30, 2023

CONCENTRATION OF CREDIT RISK

The Company's financial instruments that are exposed to concentration of credit risk consist primarily of cash and cash equivalents and certificates of deposit. The Company places its cash and temporary cash investments with high quality credit institutions. At times such investments may be in excess of the NCUA insurance limit. During the years ended September 30, 2023 and 2022 cash exceeded the federally insured amount by \$1,486,174 and \$1,693,846 respectively.

ESTIMATES

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts and disclosures. Accordingly, actual results could differ from those estimates.

PROPERTY AND EQUIPMENT

The Organization capitalizes all property and equipment with a cost of \$500 if purchased or donated as a contribution on the date received, as well as all office equipment that is technological in nature. Donations of property and equipment are recorded as support at their estimated fair market value. Property and equipment are depreciated using the straight-line method.

FINANCIAL STATEMENT PRESENTATION

Under Statement of Financial Accounting Standards (SFAS) No. 117, *Financial Statements of Not-for-Profit Organizations*, the Organization is required to report information regarding its financial position and activities according to three classes of net assets: unrestricted net assets, temporarily restricted net assets, and permanently restricted net assets. The Organization has only received unrestricted assets in the year ending September 30, 2023.

CONTRIBUTIONS

Under SFAS No. 116, *Accounting for Contributions Received and Contributions Made*, contributions received are recorded as unrestricted, temporarily restricted, or permanently restricted net assets depending on the absence or existence and nature of any donor restrictions.

LUPUS AND ALLIED DISEASES ASSOCIATION, INC.

NOTES TO FINANCIAL STATEMENTS
AT SEPTEMBER 30, 2023

INVESTMENTS

Under SFAS No. 124, *Accounting for Certain Investments Held by Not-for-Profit Organizations*, investments in marketable securities with readily determinable fair values and all investments in debt securities are reported at their fair values in the statement of financial position.

NOTE B – RESTRICTIONS ON NET ASSETS

The Organization receives contributions from Individuals and Corporations that may be restricted as to use by the Organization determined by the donor. For the year ended September 30, 2023 the Organization was not in receipt of any assets that were restricted either temporarily nor permanently. All assets were received unrestricted as to use by the Organization.

NOTE C – INVESTMENTS

The Organization held certificates of deposit with Americu Credit Union with a maturity date of February 1, 2024. The value of these certificates of deposit at September 30, 2023 and 2022 were \$111,093 and \$110,043 respectively. The Organization also held certificates of deposit with a maturity date of March 4, 2025 with a value of \$418,036, February 12, 2025 with a value of \$905,441 through Americu at September 30, 2023. The Organization also held certificates of deposit through Popular Bank with a maturity date of April 11, 2024 in the amount of 240,235, Seattle Bank with a maturity date of April 11, 2024 in the amount of 29,583 and Western Alliance bank with a maturity date of April 11, 2024 in the amount of 240,235.

NOTE D – PROPERTY AND EQUIPMENT

Property and equipment consist of the following:

	<u>2023</u>	<u>2022</u>
Office Equipment	\$ <u>5,399</u>	\$ <u>5,399</u>
Accumulated Depreciation	<u>(5,082)</u>	<u>(4,871)</u>
	<u>\$ 317</u>	<u>\$ 528</u>

NOTE E – SUBSEQUENT EVENTS

Management has evaluated subsequent events as of January 15, 2023 which is the date the financial statements were available for issuance. No events have been noted.